A Pilot Study of Digital Cognitive Behavioral Therapy for Veterans

Insomnia Clinical Trial

Official title:

A Pilot Study of Digital Cognitive Behavioral Therapy for Veterans With Insomnia and Comorbid Psychopathology

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03688763
• Other study ID #: MCC0002ARG
• Status: Active, not recruiting
• Phase: N/A
• Start date: February 5, 2018
• Est. completion date: December 30, 2022

Study information

• Verified date: November 2021
• Source: Palo Alto Veterans Institute for Research
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The proposed study is a multiple baseline design pilot study which seeks to evaluate the impact of digitally administered CBT-I, using the Sleepio platform, for the treatment of insomnia disorder among Veterans with co-morbid psychopathology. In addition, information related to acceptability and feasibility of the intervention among a Veteran sample will be obtained.

Description:

Cognitive Behavioral Therapy for Insomnia (CBT-I) is considered the front-line intervention for individuals with insomnia and has recently been rolled-out throughout the Veterans Health Administration (VHA; Manber et al., 2012). CBT-I includes behavioral (sleep restriction, stimulus control, relaxation exercises), cognitive (cognitive restructuring, mindfulness exercise), and psychoeducation (sleep hygiene) components. While CBT-I has been demonstrated to be a highly efficacious and effective intervention, it is a specialized intervention that can be costly and is in limited supply based on the level of training required and number of providers available. For this reason, digital administration of CBT-I has been examined and research has demonstrated initial efficacy among community samples (Ritterband et al., 2009; Vincent et al., 2009; Espie et al., 2012), with one platform, Sleepio, demonstrating efficacy compared to a placebo intervention (Espie et al., 2012; Espie et al., 2014). For this reason, the current study will utilize the Sleepio platform which provides an interactive, customized and tailored delivery of CBT-I.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 10
• Est. completion date: December 30, 2022
• Est. primary completion date: November 10, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Participants must be:

• at least 18 years of age (no upper age limit)

• meet DSM-5 defined criteria for insomnia disorder

• be on a stable dose of any prescription medication (including sleep medication) for at least 2 weeks prior to the in-person screening assessment

• have comorbid psychopathology (i.e., symptoms of Posttraumatic Stress Disorder (PTSD), anxiety, and/or depression)

Exclusion Criteria:

• limited mental competency (not oriented to person, place, or time) and the inability to give informed, voluntary, or written consent to participate

• high risk for sleep apnea (STOP-Bang score >/= 3)

• current or previous diagnosis of sleep apnea that is untreated

• history of moderate or severe Traumatic Brain Injury

• current substance or alcohol use disorder, moderate to severe, in the past 3 months

• current bipolar disorder

• current or lifetime psychotic disorders

• seizure disorders

• moderate to high risk of suicide in the past month

Related Conditions & MeSH terms

• Insomnia
• Sleep Initiation and Maintenance Disorders

Intervention

Behavioral:
• Cognitive Behavioral Therapy for Insomnia (CBT-i)
CBT-i is an evidence-based treatment for insomnia. Participants will receive CBT-i via online program (Sleepio).

Locations

Country	Name	City	State
United States	VA Palo Alto Health Care System	Palo Alto	California

Sponsors (2)

Lead Sponsor	Collaborator
Palo Alto Veterans Institute for Research	Big Health

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in the Insomnia Severity Index (ISI)	The ISI is used to assess self-reported insomnia severity (Bastien et al., 2001). It is a 7-item self-report scale assessing sleep problem severity over the last two weeks, rated on a 5-point scale from 0 to 4; a higher score indicates higher severity. The ISI sums scores on the 7 items (1a, 1b, 1c, 2, 3, 4, 5) for a total score range of 0 to 28.	0 weeks (baseline), 12 weeks (end of Intervention Phase), and 16 weeks (Follow-Up)
Primary	Changes in Consensus Sleep Diary (CSD)	The CSD (Carney et al., 2012) will be used to monitor self-reported sleep during the baseline phase, over the course of the digitally administered CBT-I intervention, and throughout follow-up. The CSD is a standardized sleep diary based on expert consensus and qualitative patient input.	12 weeks (end of Intervention Phase) and 16 weeks (Follow-Up)
Primary	Changes in Participant Perception of the Acceptability, Perceived Value, and Feasibility of using a Digital Modality to Treat Insomnia Symptoms	This unpublished measure requests information on the participants impressions of using digitally administered CBT-i. Questions ask about the following areas: 1) Use of the digitally administered intervention including general impressions and frequency of use, 2) Perceived value and helpfulness of the digitally administered intervention including which features of the program were perceived to be most useful and how the program impacted different aspects of insomnia and management of insomnia, 3) Impact on health (e.g., perceived impact on management of insomnia), 4) Potential enhancements (i.e. recommendations for improvements to the intervention).	12 weeks (end of Intervention Phase) and 16 weeks (Follow-Up)
Secondary	Changes in The Posttraumatic Checklist-5 (PCL-5)	The PCL-5 is a self-report measure of PTSD symptom severity (Weathers et al., 2013). The PCL is a 20-item measure which asks respondents how much they had been bothered in the prior month by their most traumatic experience. Item responses range from 0 (not very much) to 4 (extremely) with a total score range is 0-80. DSM-5 symptom cluster scores sum item scores: Cluster B (items 1-5), C (6-7), D (8-14), and E (items 15-20).	0 weeks (baseline), 12 weeks (end of Intervention Phase), and 16 weeks (Follow-Up)
Secondary	Changes in The Patient Health Questionnaire: Depression Scale (PHQ-9)	The PHQ-9 is a 9-item self-report scale assessing depression over the last two weeks (Kroenke et al., 2002). An additional item asking about global depression and interference with life activities is not included in the PHQ-9 score. Items are scored from 0 (not at all) to 3 (nearly every day), for a total score range of 0 to 27.	0 weeks (baseline), 12 weeks (end of Intervention Phase), and 16 weeks (Follow-Up)
Secondary	Changes in the Generalized Anxiety Disorder 7-Item Scale (GAD-7)	The GAD-7 is a 7-item anxiety scale (Spitzer et al., 2006) assessing symptoms over the past two weeks. Item scores range from 0 (not at all) to 3 (nearly every day). Items are summed to yield a total score.	0 weeks (baseline), 12 weeks (end of Intervention Phase), and 16 weeks (Follow-Up)
Secondary	Changes in The Brief Inventory for Psychosocial Functioning (B-IPF)	The B-IPF-7 is a 7-item measure scored from 0 (not at all) to 6 (very much) (Bovin et al., 2018). The total score is the mean of the sum of all 7 items. The B-IPF assesses social functioning, academic and occupational functioning, daily activities over the past 30 days.	0 weeks (baseline), 12 weeks (end of Intervention Phase), and 16 weeks (Follow-Up)